These innovative agents represent a significant progression in the treatment of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates promising efficacy in controlling blood glucose https://arunbmsn929889.csublogs.com/46684691/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide